新型药物洗脱支架治疗再狭窄疗效和安全性研究进展
被引量:3
摘要
自从1977年Grǔentzig第一次成功地将经皮冠状动脉腔内成形术(PTCA)应用于人体以来,经皮冠状动脉介入治疗(PCI)已成为冠心病治疗的主要手段。但PCI所带来的血管再狭窄问题却一直困扰着临床医生。药物洗脱支架(DES)成功地减少了支架内再狭窄(ISR),但其抑制血管内皮化导致的安全性问题却备受人们关注。
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2009年第5期472-475,共4页
Chinese Journal of Cardiology
基金
国家高技术研究发展计划资助项目(2007AA02Z450)
参考文献21
-
1Stone GW,Moses JW,Ellis SG,et al.Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents.N Engl J Med,007,356:998-1008.
-
2Fajadet J,Wijns W,Laarman GJ,et al.Randomized,doubleblind,multicenter study of the Endeavor zotarolimus-eluting phosphorylcholinc-encapsulated stent for treatment of native coronary artery lesions,clinical and angiographic results of the ENDEAVOR 11 trial.Circulation,2006,114:798-806.
-
3Kandzari DE,Leon MB,Popma JJ,et al.Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease:a randomized controlled trial.J Am Coil Cardiol,2006,48:2440-2447.
-
4Jain AK,Meredith IT,Lotan C,et al.Real-world safety and efficacy of the endeavor zotarolimus-eluting stent:early data from the E-Five Registry.Am J Cardiol,2007,100:77M-83M.
-
5Stone GW,Midei M,Newman W,et al.Comparison of an everolimus-eluting stent and a paclitaxcl-eluting stent in patients with coronary artery disease:a randomized trial.JAMA,2008,299:1903-1913.
-
6Biondi-Zoccai G,Lotrionte M,Moretti C,et al.Percutaneous coronary intervention with everolimns-eluting stents (Xience V):systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).Minerva Cardioangiol,2008,56:55-65.
-
7Ge J,Qian J,Wang X,et al.Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.Catheter Cardiovasc Interv,2007,69:198-202.
-
8Lee CH,Lim J,Low A,et al.Sirolimus-eluting,bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction:a clinical and angiographic study (CURAMI Registry).J Invasive Cardiol,2007,19:182-185.
-
9Krucoff MW,Kereiakes DJ,Petersen JL,et al.A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease:primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restennsis) Ⅱ study.J Am Coil Cardiol,2008,51:1543-1552.
-
10Windecker S,Serruys PW,Wandel S,et al.Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revaacularisation (LEADERS):a randomised non-inferiority trial.Lancet,2008,372:1163-1173.
同被引文献24
-
1王田蔚,方乐,赵永生,杨海山.紫杉醇可降解支架防治犬血管再狭窄的对比分析[J].中国介入影像与治疗学,2006,3(1):59-62. 被引量:3
-
2苗军,崔连群.药物洗脱支架对糖尿病小血管再狭窄的影响[J].山东医药,2006,46(31):44-45. 被引量:2
-
3谢东明,廖伟,钟一鸣,谢东阳,危小军,阳贻红,王小萍,廖永玲.经皮冠状动脉介入治疗(PCI)186例临床分析[J].赣南医学院学报,2007,27(3):339-340. 被引量:1
-
4Zacek P,Dominik J,Harrer J,et al.Morbidity and mortality in patients 70 years of age and over undergoing isolated coronary artery bypss surgery[J].Acta Medica(Hradec Kralove),2001,44(2):109-14.
-
5Cohen HA,Williams DO,Holems DR Jr,et al.Impact of age on procedural and 1-year outcome in percutanous transluminal coronary angioplasty:a report from the NHLBI Dynamic Registy[J].Am Heart,2003,146:513-9.
-
6Dieker HJ,Brouwer MA,Verheugt FW.ESC guidelines for percutaneous coronary interventions[J].Eur Heart J,2005,26(22):2475.
-
7Stone GW,Ellis,Cox DA,et al.Apolymer-based,paclitaxel-eluting stent in patients with coronary artery disease[J].N Engl J Med,2004,350(3):221-31.
-
8Degertekin M,Serruys PW,Foley DP,et al.Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation:long-term(up to 2years)clinical,angiographic,and intravascular ultrasound follow-up[J].Circulation,2002,106(13):1610-3.
-
9Laarman GJ,Suttorp MJ,Dirksen MT,et al.Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention[J].N Engl J Med,2006,335(11):1105-13.
-
10Spaulding C,Henry P,Teiger E,et al.Sirolimus-eluting versus uncoated stents in acute myocardial infarction[J].N Engl Jmed,2006,335(11):1093-104.
引证文献3
-
1徐晓东,朱永新,刘少忠,程军,方洁.经皮冠状动脉介入治疗79例临床分析[J].安徽医药,2010,14(8):922-923. 被引量:5
-
2柳元化.西罗莫司洗脱支架与金属支架植入的临床效果及血管再狭窄比较[J].中国基层医药,2011,18(9):1254-1255. 被引量:4
-
3梁宇博,林欣,车千秋,孙润民,王琼英,马俊丽,胡浩,常鹏,张春,余静,白锋.经皮冠状动脉介入治疗术中应用生物可吸收支架的安全性和有效性的系统评价[J].中国循证心血管医学杂志,2019,11(2):148-154. 被引量:7
二级引证文献16
-
1吴小星.冠心病患者冠状动脉介入术后预防复发的最佳证据总结[J].社区医学杂志,2022,20(14):803-807. 被引量:1
-
2陈多学,吴桥,江荣炎,卜令同,王敏,耿旭影,汪慧敏.经桡动脉途径介入治疗急性冠脉综合征256例[J].安徽医药,2011,15(8):980-982. 被引量:5
-
3苏良献,邓斌,黄杰雄,苏荣斌.经皮冠状动脉介入术治疗冠状动脉左主干病变疗效观察[J].中国基层医药,2012,19(6):837-838. 被引量:1
-
4邓昭武.冠心病患者不同支架术后炎性反应因子的变化[J].中国基层医药,2012,19(17):2573-2574. 被引量:1
-
5孙世博.54例冠心病患者经皮冠状动脉介入治疗效果分析[J].中外医疗,2013,32(11):45-46. 被引量:5
-
6何梅,冯达应.冠状动脉介入术后并发症发生原因与护理对策[J].中国医药导报,2014,11(19):113-115. 被引量:9
-
7张春辉,王增良.芪苈强心胶囊联合PCI术治疗冠心病冠状动脉狭窄的疗效观察[J].中医药导报,2015,21(6):87-89. 被引量:4
-
8谭晓蓉.心脑血管疾病患者抗血小板药物治疗并发上消化道出血的临床应用[J].心血管病防治知识(学术版),2015,5(7):69-70. 被引量:4
-
9肖大刚,马野,刘双.冠心病应用西罗莫司洗脱支架和金属裸支架治疗的远期效果对比分析[J].中国医疗器械信息,2016,22(04X):74-75.
-
10肖大刚,刘双,马野.冠心病应用西罗莫司洗脱支架和金属裸支架治疗的远期效果对比分析[J].铁法科技,2017,0(A01):107-109.
-
1刘晓娅,曾宏玲,卢甲盟,刘升云.托珠单抗在成人斯蒂尔病中的治疗进展[J].中华风湿病学杂志,2015,19(7):495-498. 被引量:1
-
2张璟,洪志鹏.肺移植的研究进展[J].医学综述,2004,10(7):431-433. 被引量:8
-
3周伟,乔峻.冠状动脉旁路移植术治疗冠心病的进展[J].新疆医学,2005,35(2):77-80.
-
4汤俊达.CAPD并发真菌性腹膜炎12例诊治分析[J].浙江临床医学,2004,6(9):774-774.
-
5王珊珊,黄佳亮,彭桂福,姜普林,曾年华,刘金华,朱少凡,王志斌.Natural foci of tsutsugamushi disease in the Nan Peng Lie Islands in China[J].Chinese Medical Journal,2002(2):272-275. 被引量:2
-
6李文森,杨季,康明春.视可尼喉镜“光斑法”气管插管的效果观察[J].心血管病防治知识(学术版),2015,5(5):147-148.
-
7钟守先,蔡力行,赵玉沛,梁晓明.胰头癌的外科治疗[J].临床消化病杂志,1990,2(4):178-181.
-
8王玉琦,曲乐丰.腹主动脉瘤腔内治疗的现状[J].中华外科杂志,2005,43(7):468-473. 被引量:1
-
9吴天一,李舒平,周兆年.珠峰——特高海拔高山医学的实验之地(纪念国际登顶50周年)[J].高原医学杂志,2003,13(2):2-4.